Search Results

Dimerization: Unveiling Its Role in Receptor Function and Signaling Sonja Peter , Brian Bender , Chris De Graaf for their excellent work on Comparative Study of Allosteric GPCR Binding Sites and Their Ligandability

Dimerization: Unveiling Its Role in Receptor Function and Signaling Sonja Peter , Brian Bender , Chris De Graaf   for their excellent work on Comparative Study of Allosteric GPCR Binding Sites and Their

This week's highlight includes congrats to Omolade Otun, Chris de Graaf, Cherine Bechara, et al. for

April 2022 Ono Enters into Collaboration Agreement with Domain Therapeutics and Université de Montréal (Strasbourg, France; CEO: Pascal Neuville; “Domain”) and Université de Montréal (Québec, Canada; “UdM

Tim De Groof! It’s not often when you get the best of both worlds - nano-bodies and #GPCRs.

the Department of Biochemistry and Molecular Medicine of the Faculty of Medicine of the Université de

Chris Cargill appointed as President and Chief Executive Officer • Dr.

This is the essence of de-risking GPCR programs through operational excellence. your drug discovery process from a series of disconnected efforts into a seamless, predictable, and de-risked Learn to translate your program’s internal operational precision into a compelling, de-risked narrative

De novo drug design: AI algorithms can generate new molecules with desired properties, such as binding chemical space, limiting their ability to identify truly novel chemotypes”(Thomas, Smith, O’Boyle, de Graaf & Bender, 2021) and 4) limit of input data can lead to a phenomenon called “the burden of sequence

A postdoc in Santiago de Compostela introduced her to GPCRs, and from there, things escalated quickly

conversation dives deep into the tools now transforming receptor biology—and how they’re being used to de-orphanize

success Sosei and PharmEnable extend neurological disease drugs hunt Sosei Heptares’ President & CEO Chris

INV-202, an Oral, Peripherally-acting CB1 Inverse Agonist, in Patients with Diabetic Kidney Disease Chris

Member Profile Antony Boucard Professor Centro de Investigación y de Estudios Avanzados del IPN (Cinvestav AB: Favorite Taco: Taco de suadero (pronounced swa-day-ro), fatty, with meat caramelized in its own fat

Topline Safety and Tolerability Data from Proof-of-Concept Studies Sosei Heptares’ President & CEO Chris

Boston, MA and Santiago de Compostela, Spain — [June 3rd, 2025]  — Dr.

From the scientist’s view: a conversation with … Chris Tate AI is dreaming up drugs that no one has ever

GPCR consulting that cuts through the noise, designing assay cascades, setting go/no-go points, and de-risking

Graaf, C., et al., Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March

  Madelyn N Moore , Kelsey L Person , Abigail Alwin , Campbell Krusemark , Ezequiel Marron Fernandez de loss after a year, with no plateau INAUGURATION OF AELIS FARMA NEW LABORATORY at Institut Européen de

.; Henry De Villeneuve, C.; Moraillon, A.; Ozanam, F.; Gabouze, N.; Djebbar, S.

Your pipeline depends on early, well-informed decisions that move promising candidates forward while de-prioritizing

Fluorescence Microscopy validation performed in the ONCOMET laboratory (Health Research Institute of Santiago de

L, González A, Gioé-Gallo C, Mallo-Abreu A, Brea J, Loza MI, García-Rey A, García-Mera X, Gutiérrez-de-Terán

Source: Kim J, Choi C. 2018 Feb;98:222-232. doi: 10.1016/j.biopha.2017.12.056 Azam S, Haque ME, Jakaria M, Jo SH, Kim IS, Choi Cells. 2020 Feb 23;9(2):506. doi: 10.3390/cells9020506   Kim J, Choi C.

Domain Therapeutics was nominated for the Trophée de l'Innovation Technologique (Technological Innovation

running early-stage programs, recognizing this decoupling early can sharpen dose optimization  and de-risk

Therefore, matching a ligand to an orphan GPCRs, the process of de-orphanizing, is of great importance

Michel Bouvier received the title of Doctor Honoris Causa from the Université de Montpellier Domain Therapeutics

GPCR drugmaker Septerna amasses $288M in IPO Surrounded by AI bio giants, tiny startup Nabla Bio makes de